Exploring Key Insights of the Gastroparesis Drugs Market: Growth Prospects, Emerging Trends, and Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Rapidly is the Gastroparesis Drugs Market Expected to Expand Between 2025 and 2034 Based on Current Trends?
Recent years have seen a significant growth in the market size of gastroparesis drugs. It is forecasted to increase from $5.39 billion in 2024 to $5.73 billion in 2025, representing a compound annual growth rate (CAGR) of 6.3%. Factors such as the side effects of current treatments, research into gastrointestinal motility, clinical necessity, patient advocacy, and regulatory backing have all contributed to the growth throughout the historical period.
The market for gastroparesis drugs is projected to witness robust expansion in the upcoming years. The market is anticipated to reach $7.2 billion in 2029, growing at a compound annual growth rate (CAGR) of 5.9%. Factors attributing to this growth over the forecast period are identified as escalating diabetes cases, the aging demographic, increased awareness and rates of diagnosis, a rise in healthcare spending, along with governmental and private investments. Key trends expected during the forecast period encompass developments in gastroenterology, enhanced diagnostic methods, technological progression, allocation of research funding, and joint research initiatives.
What Combination of Drivers Is Leading to Accelerated Growth in the Gastroparesis Drugs Market?
The escalating occurrence of diabetes is anticipated to fuel the expansion of the gastroparesis drugs market in the future. Diabetes is a chronic health problem characterized by elevated blood sugar levels, due to either insufficient insulin production or the body’s inefficient use of insulin. The rising occurrence of diabetes can be attributed to factors such as inactive lifestyles, unhealthy eating patterns, inheriting genes, urbanization and aging populations, amplified by insufficient healthcare access and growing global obesity rates. Patients with diabetes are often given gastroparesis drugs to mitigate complications like nausea, vomiting, and slower gastric emptying, which are common disturbances of gastrointestinal motility seen in diabetes. The aim of these drugs is to augment gastric function and improve lifestyle quality for people suffering from diabetes-induced gastroparesis. For instance, the Office for Health Improvement & Disparities, a government branch based in the UK, reported in March 2024 that between March 2022 and March 2023, the proportion of individuals with type 1 diabetes receiving all eight advised care processes rose by 22%, and for those with type 2 diabetes, it increased by 21%. Moreover, the percentage of individuals achieving target HbA1c levels spiked to 37.9%, which is the highest value recorded by the National Diabetes Audit (NDA). Thus, the heightened occurrence of diabetes is augmenting growth in the gastroparesis drugs market.
Get Your Free Sample of the Global Gastroparesis Drugs Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp
Which Key Players Are Shaping the Future of the Gastroparesis Drugs Market?
Major companies operating in the gastroparesis drugs market are:
• Amazon.com Inc._x000D_
• Alphabet Inc._x000D_
• Adobe Inc._x000D_
• Zalando SE_x000D_
• Farfetch Group Limited_x000D_
How Are the Latest Trends Influencing the Growth of the Gastroparesis Drugs Market?
Leading businesses in the gastroparesis drugs market are putting their efforts towards the introduction of inventive medications, such as Gimoti (metoclopramide) nasal spray, to acquire a beneficial position in the market. Gimoti (metoclopramide) nasal spray is a therapeutic drug designed to alleviate gastroparesis symptoms in adults by promoting better stomach emptying via improved gastrointestinal motility. This drug circumvents the gastrointestinal tract and gets absorbed directly into the bloodstream via the nasal mucosa. For instance, Evoke Pharma Inc., a pharmaceutical firm based in the United States, revealed in April 2022 that the U.S. Food and Drug Administration (FDA) conferred new drug product exclusivity for GIMOTI (metoclopramide) nasal spray. This exclusivity endows Evoke with exclusive marketing privileges for three years from the initial approval date under the Hatch-Waxman Act, safeguarding the product from generic market competition.
Get Instant Access to the Global Gastroparesis Drugs Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report
How Are Market Segments in the Gastroparesis Drugs Industry Positioned for Long-Term Growth?
The gastroparesis drugs market covered in this report is segmented –
1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs
2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes
3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types
4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration
5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce
Subsegments:
1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements
2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants
What Regions Are At the Forefront of Gastroparesis Drugs Market Expansion?
North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Can We Define the Gastroparesis Drugs Market and Its Key Components?
Gastroparesis drugs are medications used to manage and treat gastroparesis, a condition where the stomach’s ability to empty its contents is delayed, causing symptoms such as nausea, vomiting, and abdominal pain. These drugs typically include prokinetics to stimulate stomach motility, antiemetics to control nausea and vomiting, and medications to manage pain and other symptoms associated with the condition.
Browse Through More Similar Reports By The Business Research Company:
Fertility Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/fertility-drugs-global-market-report
Gastrointestinal Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/gastrointestinal-devices-global-market-report
Gastrointestinal Bleeding Treatment Devices Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
